Research ExplorerPublicationsMesothelin is Commonly Expressed in Pancreatic Adenocarcinom...

Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness

Standard

Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. / Weidemann, Sören; Perez, Daniel; Izbicki, Jakob R; Neipp, Michael; Mofid, Hamid; Daniels, Thies; Nahrstedt, Ulf; Jacobsen, Frank; Bernreuther, Christian; Simon, Ronald; Steurer, Stefan; Burandt, Eike; Marx, Andreas H; Krech, Till; Clauditz, Till S; Jansen, Kristina.

In: CANCER INVEST, Vol. 39, No. 9, 10.2021, p. 711-720.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Weidemann, S, Perez, D, Izbicki, JR, Neipp, M, Mofid, H, Daniels, T, Nahrstedt, U, Jacobsen, F, Bernreuther, C, Simon, R, Steurer, S, Burandt, E, Marx, AH, Krech, T, Clauditz, TS & Jansen, K 2021, 'Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness', CANCER INVEST, vol. 39, no. 9, pp. 711-720. https://doi.org/10.1080/07357907.2021.1943747

APA

Weidemann, S., Perez, D., Izbicki, J. R., Neipp, M., Mofid, H., Daniels, T., Nahrstedt, U., Jacobsen, F., Bernreuther, C., Simon, R., Steurer, S., Burandt, E., Marx, A. H., Krech, T., Clauditz, T. S., & Jansen, K. (2021). Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. CANCER INVEST, 39(9), 711-720. https://doi.org/10.1080/07357907.2021.1943747

Vancouver

Weidemann S, Perez D, Izbicki JR, Neipp M, Mofid H, Daniels T et al. Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. CANCER INVEST. 2021 Oct;39(9):711-720. https://doi.org/10.1080/07357907.2021.1943747

Bibtex

@article{d716b58580ed4d4784ca97572eb6b6bc,
title = "Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness",
abstract = "Data on Mesothelin (MSLN) expression in human normal and cancerous tissues is controversial. We employed immunohistochemistry (IHC) on a tissue microarray (TMA) from 599 pancreatic cancers and 12 large tissue sections of pancreatitis. MSLN expression was highest in pancreatic adenocarcinomas (89%) and adenocarcinomas of the ampulla Vateri (79%), infrequent in pancreatitis and absent in 6 acinus cell carcinomas and normal pancreas. MSLN expression was unrelated to pathological tumor stage, grade, metastasis, and tumor-infiltrating CD8+ lymphocytes. In conclusion, pancreatic cancer may be ideally suited for putative anti- MSLN therapies, and MSLN may represent a suitable biomarker for pancreatic cancer diagnosis, especially on small biopsies.",
author = "S{\"o}ren Weidemann and Daniel Perez and Izbicki, {Jakob R} and Michael Neipp and Hamid Mofid and Thies Daniels and Ulf Nahrstedt and Frank Jacobsen and Christian Bernreuther and Ronald Simon and Stefan Steurer and Eike Burandt and Marx, {Andreas H} and Till Krech and Clauditz, {Till S} and Kristina Jansen",
year = "2021",
month = oct,
doi = "10.1080/07357907.2021.1943747",
language = "English",
volume = "39",
pages = "711--720",
journal = "CANCER INVEST",
issn = "0735-7907",
publisher = "informa healthcare",
number = "9",

}

RIS

TY - JOUR

T1 - Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness

AU - Weidemann, Sören

AU - Perez, Daniel

AU - Izbicki, Jakob R

AU - Neipp, Michael

AU - Mofid, Hamid

AU - Daniels, Thies

AU - Nahrstedt, Ulf

AU - Jacobsen, Frank

AU - Bernreuther, Christian

AU - Simon, Ronald

AU - Steurer, Stefan

AU - Burandt, Eike

AU - Marx, Andreas H

AU - Krech, Till

AU - Clauditz, Till S

AU - Jansen, Kristina

PY - 2021/10

Y1 - 2021/10

N2 - Data on Mesothelin (MSLN) expression in human normal and cancerous tissues is controversial. We employed immunohistochemistry (IHC) on a tissue microarray (TMA) from 599 pancreatic cancers and 12 large tissue sections of pancreatitis. MSLN expression was highest in pancreatic adenocarcinomas (89%) and adenocarcinomas of the ampulla Vateri (79%), infrequent in pancreatitis and absent in 6 acinus cell carcinomas and normal pancreas. MSLN expression was unrelated to pathological tumor stage, grade, metastasis, and tumor-infiltrating CD8+ lymphocytes. In conclusion, pancreatic cancer may be ideally suited for putative anti- MSLN therapies, and MSLN may represent a suitable biomarker for pancreatic cancer diagnosis, especially on small biopsies.

AB - Data on Mesothelin (MSLN) expression in human normal and cancerous tissues is controversial. We employed immunohistochemistry (IHC) on a tissue microarray (TMA) from 599 pancreatic cancers and 12 large tissue sections of pancreatitis. MSLN expression was highest in pancreatic adenocarcinomas (89%) and adenocarcinomas of the ampulla Vateri (79%), infrequent in pancreatitis and absent in 6 acinus cell carcinomas and normal pancreas. MSLN expression was unrelated to pathological tumor stage, grade, metastasis, and tumor-infiltrating CD8+ lymphocytes. In conclusion, pancreatic cancer may be ideally suited for putative anti- MSLN therapies, and MSLN may represent a suitable biomarker for pancreatic cancer diagnosis, especially on small biopsies.

U2 - 10.1080/07357907.2021.1943747

DO - 10.1080/07357907.2021.1943747

M3 - SCORING: Journal article

C2 - 34143695

VL - 39

SP - 711

EP - 720

JO - CANCER INVEST

JF - CANCER INVEST

SN - 0735-7907

IS - 9

ER -